NASDAQ$SXTC

China SXT Pharmaceuticals Inc. · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Headline financials

Total Revenue

$1.93M

Previous: $3.22M-40.0%
EPS (adj)

$0.03

Previous: -$0.10+127.9%
Net Income

$691K

Previous: -$2.35M+129.4%
Operating Income

$582K

Previous: -$221K+363.6%
Gross Profit

$1.41M

Previous: $1.84M-23.3%
R&D Expense

$0.00

No prior period

Revenue & EPS history

China SXT · Revenue · Quarterly

$1.93M

Q2 2021-40%vs Q2 2020

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 13 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

-5.7%

Avg return

Earnings day

-14.5%

Avg return

5 days after

-25.4%

Avg return

30 days after

23%

3 / 13 earnings

Positive

+20.4%

Q2 2020

Best reaction

-59.0%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2024-1.0%-1.9%-36.5%
Q4 2023-1.0%-100.0%-100.0%
Q2 2023-6.9%-4.9%-30.6%
Q4 2022+2.7%-13.4%-17.1%
Q2 2022-59.0%-62.8%-65.4%
Q4 2021-10.5%-9.7%-10.5%
Q2 2021+3.6%+0.8%+11.0%
Q4 2020-6.7%-1.2%-25.0%
Q2 2020+20.4%+15.6%+13.7%
Q4 2019-5.0%-4.8%-18.6%
Q4 2018-5.0%-4.8%-18.6%
Q4 2017-5.0%-4.8%-18.6%
Q2 2019-0.5%+3.6%-14.0%
Q3 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro